STOCK TITAN

Mersana Therapeutics, Inc. - MRSN STOCK NEWS

Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-drug conjugates (ADCs) aimed at improving the lives of cancer patients. Leveraging their proprietary Fleximer platform, Mersana is rewriting the rules for immunoconjugate therapies by creating precisely targeted and highly tailored drugs. This platform allows for the custom design of ADCs with specific properties that overcome current limitations and enhance the drug's effectiveness against particular cancers, while minimizing side effects.

Mersana's lead product candidate, Upifitamab Rilsodotin (UpRi), utilizes the Dolaflexin platform and targets the NaPi2b protein, primarily for the treatment of platinum-resistant ovarian cancer. Although the UPLIFT clinical trial did not meet its primary endpoint, the company is conducting in-depth analyses to understand the results and potential future steps for UpRi.

Among its pipeline, Mersana's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, a STING agonist ADC developed using the Immunosynthen platform, which targets a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana is advancing XMT-1660 in its Phase 1 clinical trial, with plans to initiate dose expansion in 2024. For XMT-2056, Mersana has resumed enrollment in its Phase 1 clinical trial following the lifting of a clinical hold by the FDA.

Mersana collaborates with multiple partners, such as Janssen Biotech and Merck KGaA, to advance their ADC pipelines using Mersana’s innovative platforms. Additionally, the company continues to strengthen its financial position, reporting substantial cash reserves to support its operations into 2026.

With a focus on developing next-generation ADCs, Mersana remains committed to delivering meaningful clinical benefits to cancer patients through its robust pipeline and strategic partnerships.

Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN) announced it will report second quarter financial results on August 8, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on developing antibody-drug conjugates (ADCs) for cancer treatment. Management will also participate in two upcoming conferences: the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, and a SITC Webinar on August 26, 2022. The second quarter conference call can be accessed via phone or live webcast on Mersana's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
conferences
-
Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN) announced that Carla Poulson, its Senior VP and Chief People Officer, was recognized as one of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America. Since joining Mersana in 2021, Poulson has significantly contributed to the company's growth and culture, enhancing diversity and inclusion. Under her leadership, Mersana was included in The Boston Globe’s Top Places to Work in Massachusetts. Mersana specializes in developing antibody-drug conjugates for cancer treatment, with their lead candidate in trials targeting ovarian cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
none
-
Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) announced on July 1, 2022, the grant of stock options and restricted stock units (RSUs) to 8 new employees as part of its inducement program. The total awards include stock options for 25,575 shares and RSUs for 47,925 shares. The stock options have an exercise price of $4.63, matching the closing stock price on the grant date, and will vest over four years. The RSUs will vest in four equal annual installments starting May 15, 2023. This initiative aims to attract talent in the field of antibody-drug conjugates targeting cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
none
Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) announced on June 3, 2022, the grant of stock options and restricted stock units (RSUs) to 11 new employees, totaling 104,475 stock options and 72,600 RSUs. The options have an exercise price of $3.21 per share, matching the closing stock price on June 1, 2022, and will vest over four years. RSUs will vest in equal annual installments starting May 15, 2023. These awards are part of the company’s 2022 Inducement Stock Incentive Plan, aimed at attracting and retaining talent in its clinical-stage biopharmaceutical operations targeting cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, announced management presentations at three investor conferences. Key details include:

  • Cowen’s 3rd Annual Oncology Innovation Summit: June 2, 2022, at 1:00 p.m. ET.
  • Jefferies Global Healthcare Conference: June 10, 2022, at 10:00 a.m. ET.
  • The JMP Securities Life Sciences Conference: June 15, 2022, at 3:00 p.m. ET.

Webcasts will be available on Mersana's website, with archived replays for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences
-
Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN) has announced that the FDA granted orphan drug designation to its lead ADC, XMT-2056, for treating gastric cancer, which affects approximately 26,560 new cases annually in the U.S. This designation enables Mersana to receive incentives such as tax credits, user fee exemptions, and potential seven-year market exclusivity upon approval. The company plans to initiate a Phase 1 trial for XMT-2056 in mid-2022, targeting HER2-expressing tumors, with expectations for its unique mechanism to enhance treatment efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
none
Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN) reported a net loss of $47.3 million for Q1 2022, increasing from $34.7 million in Q1 2021. Cash and cash equivalents rose to $230.1 million, bolstered by a $40 million upfront payment from a collaboration with Janssen, alongside potential milestone earnings exceeding $1 billion. The company aims to advance its UpRi ADC in multiple clinical trials with expected patient dosing in Phase 1 trials for XMT-1660 and XMT-2056 commencing mid-2022. R&D expenses climbed to $35.8 million due to increased clinical activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.35%
Tags
-
Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) announced on May 2, 2022, that it granted stock options and restricted stock units (RSUs) to seven new employees who joined in April 2022. The awards include stock options for 152,100 shares at an exercise price of $3.70, with a 10-year term and a four-year vesting schedule. Furthermore, the RSUs, totaling 10,050 shares, will vest in equal installments over four years, starting May 15, 2023. These inducement awards comply with Nasdaq Listing Rule 5635(c)(4) to attract new talent to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.35%
Tags
none
-
Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced it will present business updates and financial results for Q1 2022 on May 9, 2022. A conference call will be held at 8:00 a.m. ET, accessible via phone or live webcast. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, including lead candidate upifitamab rilsodotin (UpRi) for ovarian cancer. Key trials include UPLIFT and UPGRADE, along with ongoing development of XMT-1592 and other ADCs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
conferences
Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) announced on April 1, 2022, the grant of inducement awards consisting of stock options for 51,150 shares to four new employees. These options have an exercise price of $4.32 per share, equal to the closing price on the grant date. The options vest over four years, with 25% vesting on the one-year anniversary and the rest vesting quarterly. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent in the clinical-stage biopharmaceutical company, which focuses on innovative antibody-drug conjugates targeting cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none

FAQ

What is the current stock price of Mersana Therapeutics (MRSN)?

The current stock price of Mersana Therapeutics (MRSN) is $1.3 as of January 9, 2025.

What is the market cap of Mersana Therapeutics (MRSN)?

The market cap of Mersana Therapeutics (MRSN) is approximately 160.6M.

What is Mersana Therapeutics, Inc.?

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment.

What platforms does Mersana use for its ADC development?

Mersana utilizes the Fleximer platform, Dolaflexin platform, Dolasynthen platform, and Immunosynthen platform for developing its ADCs.

What is Upifitamab Rilsodotin (UpRi)?

Upifitamab Rilsodotin (UpRi) is Mersana's lead product candidate, targeting the NaPi2b protein for treating platinum-resistant ovarian cancer.

What are XMT-1660 and XMT-2056?

XMT-1660 is a Dolasynthen ADC targeting B7-H4, and XMT-2056 is an Immunosynthen ADC targeting a novel HER2 epitope. Both are in Phase 1 clinical trials.

What recent clinical trial updates did Mersana report?

Mersana reported that the UPLIFT trial for UpRi did not meet its primary endpoint and announced plans for further analysis. Enrollment in the Phase 1 trial of XMT-2056 has resumed after the FDA lifted a clinical hold.

Who are Mersana's strategic partners?

Mersana partners with Janssen Biotech, Merck KGaA, and other companies to advance their ADC pipelines using Mersana’s platforms.

What is the Fleximer platform?

The Fleximer platform is Mersana’s proprietary technology that custom designs ADCs with specific properties to improve their effectiveness against cancer cells and reduce side effects.

What is Mersana's financial outlook?

Mersana has reported substantial cash reserves to support its current operating plan commitments into 2026, ensuring financial stability for its ongoing projects.

What are Mersana's future plans for XMT-1660?

Mersana plans to complete the dose escalation portion of the Phase 1 clinical trial of XMT-1660 in 2023 and initiate the dose expansion portion in 2024.

Where can investors find more information about Mersana?

Investors can find more information on the 'Investors & Media' section of Mersana’s website at www.mersana.com.
Mersana Therapeutics, Inc.

Nasdaq:MRSN

MRSN Rankings

MRSN Stock Data

160.59M
101.83M
11.78%
102.08%
7.21%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE